Compare Fox Corp Class A (FOXA) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class A vs Incyte Corporation — how do they compare? Fox Corp Class A trades at $62.41 (market cap $25.36B), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Fox Corp Class A and Incyte Corporation are close in size by market cap, and Fox Corp Class A pays a 0.91% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class A for 34 Days and Incyte Corporation for 33 Days on average.
| FOXA | INCY | |
|---|---|---|
Market Cap | $25.36B | $22.85B |
Volume | 2,566,954 | 1,927,029 |
Sector | Media | Health |
52-Week High | $76.11 | $129.93 |
52-Week Low | $48.79 | $83.80 |
Typical Hold Time | 34 Days | 33 Days |
Enterprise Value | $28.72B | $18.35B |
Dividend Yield | 0.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOXA trades at $62.41, down 0.46% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 16.3% revenue growth to $16.30B in 2025 and three consecutive quarterly earnings beats. The pending $22B Roku acquisition, currently under DOJ review, represents a major strategic development. Analyst consensus is bullish with a $72.00 price target and no sell ratings among 48 analysts.
The outlook is positive given strong earnings momentum, reasonable valuation (P/E 16.55), and potential upside from the Roku deal. Key risks include regulatory hurdles for the acquisition and a projected decline in 2026 net income. The stock offers a compelling risk-reward profile for investors seeking exposure to media consolidation.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class A
Fox operates in cable networks and television. Its cable segment includes Fox News, Fox Business, and sports channels, while its TV segment covers the Fox network, 29 local stations (18 Fox-affiliated), and the ad-supported streaming service Tubi. After selling most of its entertainment assets to Disney in 2019, Fox now focuses on live news and sports, primarily within pay-TV. The Murdoch family controls the company.
Read more on FOXA →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
